Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection

Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine

Volumn 69, Issue 5, 2014, Pages 358-366

  De Keyser, E ^a   De Keyser, F ^b   De Baets, F ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Diagnosis; Interferon gamma release assay; Meta analysis; Tuberculin skin test; Tuberculosis

Indexed keywords

GAMMA INTERFERON; TUBERCULIN;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; GOLD STANDARD; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUBERCULIN TEST; ADULT; CHILD; FEMALE; MALE; MIDDLE AGED; PRESCHOOL CHILD; TUBERCULOSIS; YOUNG ADULT;

ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 84918767322     PISSN: 17843286     EISSN: 22953337     Source Type: Journal    
DOI: 10.1179/2295333714Y.0000000043     Document Type: Article

References (47)

1. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Care Med. 2013;34(1):3-16.
2. Nicod LP. Immunology of tuberculosis. Swiss Med Wkly. 2007;137(25-26):357-62.
3. Norbis L, Miotto P, Alagna R, Cirillo DM. Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiol. 2013;36(2):111-20.
4. Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2010;69(4):782-4.
5. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40(4):990-1013.
6. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun. 2011;37(4):273-88.
7. Keystone EC, Papp KA, Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol. 2011;38(7):1234-43.
8. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: European Centre for Disease Prevention and Control; 2011. Available from: http://ecdc.europa.eu/en/publications/publications/1103-gui-igra.pdf (accessed 15 Sept 2013).
9. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2011;15(8):1018-32.
10. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099-104.
11. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection. MMWR Recomm Rep. 2010;59:1-25.
12. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010;137(4):952-68.
13. Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br Med Bull. 2010;93:69-84.
14. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.
15. StatsDirect Ltd. StatsDirect statistical software. Cheshire: StatsDirect Ltd; 2013. Available from: http://www.statsdirect.com (accessed 1 Apr 2013).
16. Cumming G. Inference by eye: reading the overlap of independent confidence intervals. Stat Med. 2009;28(2):205-20.
17. Rose MV, Kimaro G, Nissen TN, Kroidl I, Hoelscher M, Bygbjerg IC, et al. QuantiFERONH-TB gold in-tube performance for diagnosing active tuberculosis in children and adults in a high burden setting. PLoS One. 2012;7(7):e37851.
18. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. Intern Med. 2012;51(10):1199-205.
19. Gonzalez-Salazar F, Vargas-Villarreal J, Garcialuna-Martinez FJ, Rivera G, Moreno-Trevino MG, Montfort-Gardeazabal JM, et al. Snapshot of Quantiferon TB gold testing in Northern Mexico. Tuberculosis (Edinb). 2011;91(Suppl 1):34-7.
20. Yassin MA, Petrucci R, Garie KT, Harper G, Arbide I, Aschalew M, Merid Y, et al. Can interferon-gamma or interferon-gamma-induced-protein-10 differentiate tuberculosis infection and disease in children of high endemic areas? PLoS One. 2011;6(9):e23733.
21. Moyo S, Isaacs F, Gelderbloem S, Verver S, Hawkridge AJ, Hatherill M, et al. Tuberculin skin test and QuantiFERONH assay in young children investigated for tuberculosis in South Africa. Int J Tuberc Lung Dis. 2011;15(9):1176-81.
22. Chung JH, Han CH, Kim CJ, Lee SM. Clinical utility of QuantiFERON-TB GOLD In-Tube and tuberculin skin test in patients with tuberculous pleural effusions. Diagn Microbiol Infect Dis. 2011;71(3):263-6.
23. Rangaka MX, Gideon HP, Wilkinson KA, Pai M, Mwansa-Kambafwile J, Maartens G, et al. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. Eur Respir J. 2012;39(1):163-71.
24. Lee JE, Kim HJ, Lee SW. The clinical utility of tuberculin skin test and interferon-gamma release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infect Dis. 2011;11:96.
25. Tsolia MN, Mavrikou M, Critselis E, Papadopoulos NG, Makrinioti H, Spyridis NP, et al. Whole blood interferongamma release assay is a useful tool for the diagnosis of tuberculosis infection particularly among Bacille Calmette Guerin-vaccinated children. Pediatr Infect Dis J. 2010;29(12):1137-40.
26. Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect. 2010;61(2):133-43.
27. Syed Ahamed Kabeer B, Raman B, Thomas A, Perumal V, Raja A. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One. 2010;5(2):e9051.
28. Feng Y, Diao N, Shao L, Wu J, Zhang S, Jin J, et al. Interferon-gamma release assay performance in pulmonary and extrapulmonary tuberculosis. PLoS One. 2012;7(3):e32652.
29. Yang FF, Tu ZQ, Fang YM, Li Y, Peng Y, Dong T, et al. Monitoring of peptide-specific and gamma interferon-productive T cells in patients with active and convalescent tuberculosis using an enzyme-linked immunosorbent spot assay. Clin Vaccine Immunol. 2012;19(3):401-10.
30. Jafari C, Kessler P, Sotgiu G, Ernst M, Lange C. Impact of a Mycobacterium tuberculosis-specific interferon-gamma release assay in bronchoalveolar lavage fluid for a rapid diagnosis of tuberculosis. J Intern Med. 2011;270(3):254-62.
31. Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, Smith KC. Comparing the tuberculin skin test and T-SPOT.TB blood test in children. Pediatrics. 2011;127(1):e31-8.
32. Dilektasli AG, Erdem E, Durukan E, Eyuboglu FO. Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country? Jpn J Infect Dis. 2010;63(6):433-6.
33. Sun L, Yan HM, Hu YH, Jiao WW, Gu Y, Xiao J, et al. IFNgamma release assay: a diagnostic assistance tool of tuberculin skin test in pediatric tuberculosis in China. Chin Med J (Engl). 2010;123(20):2786-91.
34. Zhang S, Shao L, Mo L, Chen J, Wang F, Meng C, et al. Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clin Vaccine Immunol. 2010;17(12):1985-90.
35. Simsek H, Alpar S, Ucar N, Aksu F, Ceyhan I, Gozalan A, et al. Comparison of tuberculin skin testing and T-SPOT.TB for diagnosis of latent and active tuberculosis. Jpn J Infect Dis. 2010;63(2):99-102.
36. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012.
37. Fitzgerald D, Sterling T, Haas D. Mycobacterium tuberculosis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Volume 2. 7th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009. p. 3129-63.
38. Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M. Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract. 2012;21(1):4-13.
39. ATS/CDC Statement Committee on Latent Tuberculosis Infection. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1-51.
40. Geldenhuys H, Verver S, Surtie S, Hatherill M, van Leth F, Kafaar F, et al. The tuberculin skin test: a comparison of ruler and calliper readings. Int J Tuberc Lung Dis. 2010;14(10):1266-71.
41. Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R, Wood K, et al . Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment. Clin Vaccine Immunol. 2012;19(8):1243-7.
42. Banfield S, Pascoe E, Thambiran A, Siafarikas A, Burgner D. Factors associated with the performance of a blood-based interferon-c release assay in diagnosing tuberculosis. PLoS One. 2012;7(6):e38556.
43. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247.
44. Ling DI, Pai M, Davids V, Brunet L, Lenders L, Meldau R, et al. Are interferon-c release assays useful for diagnosing active tuberculosis in a high-burden setting? Eur Respir J. 2011;38(3):649-56.
45. Jung JY, Lim JE, Lee HJ, Kim YM, Cho SN, Kim SK, et al. Questionable role of interferon-c assays for smear-negative pulmonary TB in immunocompromised patients. J Infect. 2012;64(2):188-96.
46. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100-11.
47. Baeten D, Kruithof E, van den Bosch F, van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62(9):829-34.